These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38428479)

  • 1. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
    Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
    Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
    Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
    Rindone JP; Mellen CK
    Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
    Lefèvre B; Hoen B; Goehringer F; Sime WN; Aissa N; Alauzet C; Jeanmaire E; Hénard S; Filippetti L; Selton-Suty C; Agrinier N;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2605-2616. PubMed ID: 34383175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
    Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of a cefazolin inoculum effect associated with blaZ gene types, and clinical outcomes among methicillin-susceptible Staphylococcus aureus blood isolates of patients with infective endocarditis.
    Bourreau A; Le Mabecque V; Broquet A; Caillon J
    Infect Dis Now; 2023 Feb; 53(1):104626. PubMed ID: 36184048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
    Willekens R; Puig-Asensio M; Suanzes P; Fernández-Hidalgo N; Larrosa MN; González-López JJ; Rodríguez-Pardo D; Pigrau C; Almirante B
    J Antimicrob Chemother; 2022 Jul; 77(8):2288-2295. PubMed ID: 35552420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study'-author's reply.
    Lecomte R; Deschanvres C; Coudol S; Wargny M; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Aug; 27(8):1180-1181. PubMed ID: 33813113
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al.
    Buis DTP
    Clin Microbiol Infect; 2021 Aug; 27(8):1179. PubMed ID: 33581355
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
    Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX
    Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
    Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
    Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefazolin versus cloxacillin in methicillin-susceptible Staphylococcus aureus endocarditis: Too good to be true? Authors' reply.
    Herrera-Hidalgo L; de Alarcón A
    Int J Infect Dis; 2024 May; 142():106979. PubMed ID: 38401779
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
    Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
    Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia.
    Davis JS; Turnidge J; Tong S
    Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
    Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
    Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible
    Burdet C; Loubet P; Le Moing V; Vindrios W; Esposito-Farèse M; Linard M; Ferry T; Massias L; Tattevin P; Wolff M; Vandenesch F; Grall N; Quintin C; Mentré F; Duval X; Lescure FX;
    BMJ Open; 2018 Sep; 8(8):e023151. PubMed ID: 30173161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J; Echevarria KL; Traugott KA
    Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Ulloa ER; Singh KV; Geriak M; Haddad F; Murray BE; Nizet V; Sakoulas G
    Clin Infect Dis; 2020 Sep; 71(6):1413-1418. PubMed ID: 31773134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections.
    Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR
    Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.